BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 29, 2010
View Archived Issues
IntraCellular Therapies claims new PDE 1 inhibitors
Read More
Roche discloses novel PDE 10A inhibitors
Read More
Exelixis patents S1P1 receptor agonists for autoimmune diseases
Read More
Merck & Co. and Mochida claim new coagulation factor IXa inhibitors
Read More
Phase III data released on tanezumab in knee osteoarthritis pain
Read More
SB-1518 dose selected for phase II evaluation in myelofibrosis
Read More
Interim phase II data reported on ENB-0040 in childhood hypophosphatasia
Read More
Pooled phase III data show efficacy of tesamorelin in HIV-related lipodystrophy
Read More
Pilot trial finds XOMA-052 beneficial in uveitis of Behcet's disease
Read More
TroVax to be evaluated in mesothelioma in phase I/II trial
Read More
CHMP recommends approval of Shire's VPRIV for type 1 GD
Read More
Gilead signs definitive agreement to acquire CGI Pharmaceuticals
Read More
AstraZeneca and MMV join to identify antimalaria candidates
Read More
CHMP recommends approval of Sycrest for bipolar disorder
Read More
Revlimid approved in Japan for relapsed or refractory multiple myeloma
Read More
Pfizer suspends osteoarthritis program for tanezumab
Read More
MorphoSys and Xencor collaborate on mAb for B-cell malignancies
Read More
FDA sets new decision date for motavizumab BLA
Read More
Basilea presents update on phase III isavuconazole program
Read More
CHMP confirms previous negative opinion for ceftobiprole
Read More
CHMP recommends approval of vernakalant for atrial fibrillation
Read More
Pariet approved in Japan for nonerosive GERD
Read More
Galderma discloses new tyrosinase inhibitors
Read More
Corcept nears enrollment completion in phase III Corlux trial
Read More
EMA's CHMP issues positive opinion for Pharming's Rhucin
Read More